Your session is about to expire
← Back to Search
BGB-24714 + Combination Therapies for Solid Tumors
Study Summary
This trial is testing a new cancer drug, BGB-24714, to see if it is safe and effective. The study will enroll people with advanced or metastatic solid tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not had major surgery within the last 28 days.I have not had a serious infection needing treatment in the last 2 weeks.My organs are functioning well.I do not have active brain metastasis or untreated brain cancer spread.My advanced cancer cannot be surgically removed and I've either tried standard treatments without success or can't tolerate them.I haven't taken steroids or immunosuppressants in the last 14 days.I haven't had any cancer other than the one being studied within the last 3 years.I can provide a sample of my tumor, either previously stored or newly taken.I have been treated with Smac mimetics or similar drugs before.I am fully active and can carry on all my pre-disease activities without restriction.
- Group 1: Phase 1b: Dose Expansion
- Group 2: Phase 1a: Dose Escalation Part C
- Group 3: Phase 1a: Dose Escalation Part D
- Group 4: Phase 1a: Dose Escalation Part A-CN
- Group 5: Phase 1a: Dose Escalation Part E
- Group 6: Phase 1a: Dose Escalation Part A
- Group 7: Phase 1a: Dose Escalation Part B
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To what degree could BGB-24714 endanger human health?
"Considering the minimal amount of data available on BGB-24714, our team at Power has assigned a safety score of 1 to this compound. This is due to it being in Phase 1 clinical trials, thus yielding limited evidence for both efficacy and safety."
Does this investigation have openings for new participants?
"Affirmative. Clinicaltrials.gov records show that this clinical trial is currently enrolling participants–it was initially posted on July 6th 2022 and most recently updated on August 19th of the same year. A total of 244 subjects are needed to be recruited from 4 different medical sites."
How many hospitals are offering this trial to patients within the state?
"The trial is primarily based out of Massachusetts General Hospital in Boston, Tennessee Oncology PLLC in Nashville and the University of Washington in Seattle. Additionally, it has 4 other sites spread across the nation."
What is the current size of this trial's participant pool?
"Affirmative. Clinicaltrials.gov has evidence of this clinical trial actively searching for participants, beginning on July 6th 2022 and most recently being updated on August 19th 2022. This study aims to recruit 244 patients from 4 sites."
Share this study with friends
Copy Link
Messenger